Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma

Abstract

Background:Cisplatin and other anticancer drugs are important in the treatment of head and neck squamous cell carcinoma; however, some tumours develop drug resistance. If chemoresistance could be determined before treatment, unnecessary drug administration would be avoided. Here, we investigated chemoresistance factors by comprehensive analyses at the protein level. Methods:Four human carcinoma cell lines were used: cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR with acquired cisplatin resistance, naturally cisplatin-resistant UM-SCC-81B, and UM-SCC-23/WR with acquired 5-fluorouracil resistance. Extracted proteins were labelled with iTRAQ and analysed by tandem mass spectrometry to identify resistance. Protein expression was confirmed by western blotting and functional analysis was carried out using siRNA.Results:Thirteen multiple-drug resistance proteins were identified, as well as seven proteins with specific resistance to cisplatin, including enolase. Differential expression of these proteins in cisplatin-resistant and-sensitive cell lines was confirmed by western blotting. Functional analysis for enolase by siRNA showed that cisplatin sensitivity significantly was increased in UM-SCC-81B and slightly in UM-SCC-23-CDDPR but not in UM-SCC-23/WR cells.Conclusions:We identified proteins thought to mediate anticancer drug resistance using recent proteome technology and identified enolase as a true cisplatin chemoresistance factor. Such proteins could be used as biomarkers for anticancer agent resistance and as targets of cancer therapy. © 2014 Cancer Research UK. All rights reserved.